DEDICATED EXPERTS ADVANCING PRECISION THERAPIES TO THE CLINIC
FinsnoBio's small molecule therapeutic strategy is built on decades of research and a relentless focus on genetic causes of neurodegeneration.
LRRK2 is a large, multi-domain protein kinase.
Human Genetic mutations in the kinase domain at G2019S lead to kinase hyperactivity and Parkinson’s Disease. Specific Inhibition of the hyperactive kinase will stop disease progression in G2019S patients.
FinsnoBio is advancing G2019S specific kinase inhibitors to alleviate PD progression in G2019S patients and provide a safer option than Type I inhibitors.
Hyperactive kinase activity has been observed in sporadic PD patients, suggesting a role for LRRK2 inhibition in the broader PD population.
FinsnoBio advancing Type II kinase inhibitors, to avoid lung toxicity seen with other Type I inhibitors.
Graphical abstract of LRRK2 therapeutic strategy .
GENE THERAPY PIPELINE
Our pioneering small molecules are making rapid progress toward IND and human proof-of-concept.
Fueling this entire effort, FinsnoBio’s drug discovery platform combines the world’s most advanced technologies with our team’s unmatched expertise. AI-driven In Silico screening, cryo-EM, and traditional high-throughput compound screening work in concert to capture the full range of therapeutic possibilities for patient benefit.